πŸ‡ΊπŸ‡Έ FDA
Patent

US 9980904

Dry powder formulation

granted A61KA61K31/00A61K31/137

Quick answer

US patent 9980904 (Dry powder formulation) held by Teva Branded Pharmaceutical Products R&D, Inc. expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Teva Branded Pharmaceutical Products R&D, Inc.
Grant date
Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/00, A61K31/137, A61K31/167, A61K31/56